Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

December 13, 2018

Study Completion Date

December 13, 2018

Conditions
ST Segment Elevation Myocardial InfarctionPercutaneous Coronary Intervention
Interventions
DRUG

Cangrelor

Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.

OTHER

Placebo

Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

University of Florida

OTHER

NCT03247738 - Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI | Biotech Hunter | Biotech Hunter